康寧傑瑞製藥-B(09966.HK)及3D MEDICINES(01244.HK)授出KN035開發許可
康寧傑瑞製藥-B(09966.HK)全資附屬公司江蘇康寧傑瑞,及3D MEDICINES(01244.HK)非全資附屬公司思路迪醫藥,與印度上市的製藥公司Glenmark訂立許可協議,同意向Glenmark授予KN035(恩沃利單抗注射液,商標「恩維達」)腫瘤適應症的獨家許可及再授權,於印度及亞太區(新加坡、泰國及馬來西亞除外)、中東及非洲、俄羅斯、獨聯體及拉丁美洲開發KN035,以實現腫瘤所有使用領域的商業化。Glenmark將自行承擔在地區內開發及商業化KN035的開支。
根據許可協議,江蘇康寧傑瑞及思路迪將收取合共7億美元不可退還預付款及視乎進展的里程碑款;及按KN035淨銷售額計算的特許權使用費。
江蘇康寧傑瑞保留於地區內外生產KN035的獨家權利。思路迪保留在該地區以外於腫瘤領域開發及商業化KN035的權利。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.